» Authors » Andreas Liebl

Andreas Liebl

Explore the profile of Andreas Liebl including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 398
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Philis-Tsimikas A, Aroda V, De Block C, Billings L, Liebl A, Sivarathinasami R, et al.
J Diabetes Sci Technol . 2023 Jan; 18(3):653-659. PMID: 36710452
Background: Derived time in range (dTIR), calculated from self-monitored blood glucose (SMBG-dTIR) profiles, has demonstrated correlation with risk of cardiovascular and microvascular complications. This post hoc analysis of the DUAL...
2.
Mehta R, Billings L, Liebl A, Vilsboll T
Diabet Med . 2022 Jun; 39(9):e14901. PMID: 35708737
Aims: Two fixed-ratio combinations (FRCs) of basal insulin and glucagon-like peptide-1 receptor agonist (GLP-1RA) are available for once-daily use in adults with type 2 diabetes. We aimed to review the...
3.
Polonsky W, Arora R, Faurby M, Fernandes J, Liebl A
Diabetes Ther . 2021 Dec; 13(1):175-187. PMID: 34918213
Introduction: Reducing dosing frequency may lower treatment burden and improve persistence and adherence. This retrospective, observational study assessed persistence and adherence in patients with type 2 diabetes (T2D) initiating once-weekly...
4.
Haapakangas A, Hongisto V, Liebl A
Indoor Air . 2020 Aug; 30(6):1130-1146. PMID: 32735743
Irrelevant background speech causes dissatisfaction and impairs cognitive performance in open-plan offices. The model of Hongisto (2005, Indoor Air, 15, 458-468) predicts the relation between cognitive performance and the intelligibility...
5.
Harris S, Abrahamson M, Ceriello A, Charpentier G, Evans M, Lehmann R, et al.
Drugs . 2020 Jan; 80(2):147-165. PMID: 31960258
Therapeutic inertia is a substantial obstacle to the initiation of insulin therapy in people with uncontrolled type 2 diabetes (T2D). This effect has in part been perpetuated by concerns over...
6.
Rieger C, Kurz K, Mueller-Hoffmann W, Gehr B, Liebl A
J Diabetes Sci Technol . 2019 Jun; 13(6):1158-1160. PMID: 31195815
Insulin-dependent diabetes mellitus is treated with intensive insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion with insulin pumps. For people with diabetes who cannot achieve acceptable glycemic...
7.
Tibaldi J, Hadley-Brown M, Liebl A, Haldrup S, Sandberg V, Wolden M, et al.
Diabetes Obes Metab . 2018 Dec; 21(4):1001-1009. PMID: 30552800
Aims: To compare the real-world effectiveness of insulin degludec (degludec) and glargine 300 units/mL (glargine U300) in insulin-naïve adult patients with type 2 diabetes in routine US clinical practice. Materials...
8.
Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, et al.
Endocr Pract . 2018 Nov; 25(2):144-155. PMID: 30383495
Objective: The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients...
9.
Renz T, Leistner P, Liebl A
J Acoust Soc Am . 2018 Sep; 144(2):EL83. PMID: 30180670
Sound masking can diminish the performance impairment due to background speech in open-plan offices. This paper compares a steady-state masking sound with the spectrum of the disturbing speech signal to...
10.
Renz T, Leistner P, Liebl A
J Acoust Soc Am . 2018 Apr; 143(3):EL212. PMID: 29604706
Sound masking can reduce the distraction due to ambient sounds in open-plan offices. This paper compares a typical masking sound with a slope of -5 dB per octave to a...